Content area

|
|

Carcinoma in situ i mammae

Forfatter(e)
Marica Skaar, Linnea Langhans, Birgitte Mertz & Niels Kroman Brystkirurgisk Afdeling, Rigshospitalet

Ugeskr Læger 2018;180:V01170084
Reference: 
Ugeskr Læger 2018;180:V01170084
Blad nummer: 

Marica Skaar, Linnea Langhans, Birgitte Mertz & Niels Kroman:

Ductal carcinoma in situ

Ugeskr Læger 2018;180:V01170084

Ductal carcinoma in situ (DCIS) is a premalignant lesion in the breast. It is often asymptomatic and diagnosed by screening mammography. DCIS is treated in line with low-risk invasive breast cancer including mastectomy or breast conserving treatment plus radiotherapy, implicating a risk of both physical and psychological side effects. Since only a part of DCIS lesions develop into invasive cancer, some women suffer from overtreatment. However, it remains yet to be identified, in which subgroup of women with DCIS treatment can safely be omitted. We need to know more about the natural course of DCIS and develop tools to tailor treatment individually.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Christian F. Asmussen | 15/07
1 Kommentar
af Christian F. Asmussen | 15/07
1 Kommentar
af Tom Buur | 15/07
1 Kommentar
af Jørgen Alving | 12/07
2 kommentarer
af Mogens Holbech Dahl | 10/07
3 kommentarer
af Mathias Amdi Hertz | 08/07
2 kommentarer
af Elisabeth Sirkka Augustina Bright | 06/07
2 kommentarer
af Lars Høj | 06/07
1 Kommentar
af Christian E. H. R. Freitag | 04/07
8 kommentarer